Virtus Biotech ETF
BBP
19 hedge funds and large institutions have $9.1M invested in Virtus Biotech ETF in 2017 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 5 reducing their positions, and 3 closing their positions.
48% more capital invested
Capital invested by funds: $6.16M → $9.1M (+$2.94M)
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
5.72% more ownership
Funds ownership: 17.22% → 22.95% (+5.7%)
6% more funds holding
Funds holding: 18 → 19 (+1)
0% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$972K |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$813K |
| 3 |
Jane Street
New York
|
+$673K |
| 4 |
PAG
Private Advisor Group
Morristown,
New Jersey
|
+$390K |
| 5 |
VKH
Virtu KCG Holdings
New York
|
+$378K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$470K |
| 2 |
LPL Financial
San Diego,
California
|
-$212K |
| 3 |
AG
Advisor Group
Phoenix,
Arizona
|
-$112K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$85.5K |
| 5 |
FDCDDQ
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
|
-$45.7K |
BBP Hedge Fund Activity: Q2 2017 in Review
19 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Virtus Biotech ETF (BBP) for Q2 2017, worth a combined $9.1M — up 48% from $6.16M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new BBP positions and 3 closed out — a net gain of 1 holder — while 5 added to existing stakes and 5 trimmed.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $972K. The largest seller was Citadel Advisors, exiting entirely with an estimated $470K sold.
- 19 institutional investors held Virtus Biotech ETF (BBP) as of Q2 2017, up from 18 in Q1 2017.
- Funds reported $9.1M of Virtus Biotech ETF stock for Q2 2017, up 48% quarter-over-quarter.
- 4 funds opened new Virtus Biotech ETF positions in Q2 2017 and 3 closed out, a net change of +1 holder.
- The largest Virtus Biotech ETF buyer in Q2 2017 was Susquehanna International Group, an estimated $972K added.
- The largest Virtus Biotech ETF seller in Q2 2017 was Citadel Advisors, an estimated $470K sold.
Based on aggregated 13F filings for Q2 2017.